ABSTRACT
Wnt-activated medulloblastoma (MB) confers an excellent prognosis. However, specific treatment strategies for patients with relapsed Wnt-MB are unknown. We report two patients with recurrent beta-catenin nucleopositive Wnt-MB successfully treated by incorporating marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue (HDCx/AuHPCR). We also present a review of the literature for previously reported cases of relapsed Wnt-MB. We propose that patients with recurrent Wnt-MB may be treated using a multi-disciplinary approach that includes HDCx/AuHPCR with or without re-irradiation.
Subject(s)
Brain Neoplasms , Cerebellar Neoplasms , Medulloblastoma , Bone Marrow , Brain Neoplasms/therapy , Cerebellar Neoplasms/diagnostic imaging , Cerebellar Neoplasms/therapy , Hematopoietic Stem Cells , Humans , Medulloblastoma/diagnostic imaging , Medulloblastoma/therapyABSTRACT
1,4-Disubstituted-1H-1,2,3-triazoles 1 can easily be distinguished from the isomeric 1,5-disubstituted-1H-1,2,3-triazoles 2 by simple one-dimensional (13)C NMR spectroscopy using gated decoupling. The C(5) signal of 1 appears at δ â¼120 ppm, while the C(4) signal of 2 appears at δ â¼133 ppm. Computational studies also predict the upfield shift of C(5) of 1 relative to C(4) in 2.